
DOODENHE DOZILOŁ

5

A compound of the Formula IA, IB, IIA, IIB, IIIA or IIIB: 1.



wherein:

 $R^1$  is selected from the group consisting of  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  5 cycloalkylalkyl and benzyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence from  $C_1$ - $C_3$  alkyl, halogen, -CN, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

 $R^2$  is selected from the group consisting of H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl and  $C_1$ - $C_6$  haloalkyl;

 $R^3$  is selected from the group consisting of H, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_3$ - $C_6$  cycloalkyl, wherein  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_3$ - $C_6$  cycloalkyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from  $OR^8$  and  $NR^8R_1^7$ ;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected at each occurrence thereof from the group consisting of H, halogen, - OR<sup>10</sup>, -NO<sub>2</sub>, NR<sup>10</sup>R<sup>11</sup>, -NR<sup>10</sup>C(O)R<sup>11</sup> -NR<sup>10</sup>C(O)NR11R<sup>12</sup>, -S(O)<sub>R</sub>R<sup>11</sup>, -CN, -C(O)R<sup>11</sup>, -C(O)<sub>2</sub>R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, wherein each of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, =O, -CN, -OR<sup>8</sup>, -NR<sup>8</sup>R<sup>9</sup> and phenyl, and wherein phenyl is optionally substituted 1-3 substituents selected independently at each occurrence from Alogen, -CN, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

alternatively  $R^5$  and  $R^6$  are  $-\sqrt{9}-C(R^{11})_2-0-$ ;

 ${\ensuremath{\mathsf{R}}}^7$  is selected from the group consisting of H, halogen and  ${\ensuremath{\mathsf{OR}}}^{10};$ 

5

10

R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group  $C_1-C_4$  ålkyl,  $C_1-C_4$ haloalkyl, consisting of Η, alkoxyalkyl,  $C_1-C_4$  alkoxyalk $\sqrt[4]{1}$ lalkyl,  $C_3-C_6$  cycloalkyl,  $-C(0)R^{12}_{i}$ , phenyl and benzyl, wherein cylcoalkylalkyl, phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, cyano,  $C_1-C_4$  alkyl $\int C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxy and  $C_1-C_4$  haloalkoxy, or  $R^8$  and  $R^9$  are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperazine, \(\lambda\_N\)-methylpiperazine, morpholine, or thiomorpholine ring;

COOCEDIANTS COLLORS

 $R^{10}$  is selected from the group consisting of H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, -C(O) $R^{12}$ , phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxy and  $C_1$ - $C_4$  haloalkoxy;

25

 $R^{11}$  is selected from the group consisting of H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, phenyl and benzyl, where phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, -NH<sub>2</sub>, -OH,

cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy, or R<sup>10</sup> and R<sup>11</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, N-methylpiperazine, morpholine, or thiomorpholine ring, with the proviso that only one of R<sup>8</sup> and R<sup>9</sup> or R<sup>10</sup> and R<sup>11</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperaine, N-methylpiperazine, morpholine, or thiomorpholine ring;

 $R^{12}$  is selected from the group consisting of  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl and phenyl;

X is selected from the group consisting of 0,  $NR^{13}$  and S, with the proviso that X is not  $NR^{13}$  when a compound is of Formula (IA);

n is 0, 1, or 2; and,

 $R^{13}$  is selected from the group consisting of H,  $C_1$ - $C_6$  alkyl, benzyl and phenyl, wherein  $C_1$ - $C_6$  alkyl, benzyl and phenyl are optionally substituted with 1-3 substituents independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxy and  $C_1$ - $C_4$  haloalkoxy.

25

- 2. The compound of claim 1, wherein  $R^1$  is  $C_1$ - $C_6$  alkyl.
- 3. The compound of claim 2, wherein  $R^1$  is  $CH_3$ .

- The compound of claim  $1/\sqrt{1}$ , wherein  $R^2$  is H,  $C_1-C_6$  alkyl,  $C_3-$ 4.  $C_6$  cycloalkyl, or  $C_1$ - $C_6$  haloalkyl.
- The compound of claim  $A_i$  wherein  $R^2$  is H or  $C_1$ - $C_6$  alkyl. 5.
- The compound of claim 5, wherein  $R^2$  is H. 6.
- The compound of claim, 1, wherein R3 is at each occurrence 7. thereof independently H, halogen, C1-C6 alkyl, or C1-C6 alkyl substituted with from 1 to 3 of  $OR^8$  or  $NR^8R^9$ .
- The compound of claim 7, wherein  $R^3$  is H or  $C_1-C_6$  alkyl. 8.
- The compound of claim 8, wherein R3 is H. 9.
- The compound of q aim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  is H and  $R^3$ 10. is H.
- 109902945 DYLLOL The compound of claim 1, wherein  $R^4$ ,  $R^5$  and  $R^6$  are each 11. independently  $H/\!\!/$  halogen,  $C_1$ - $C_6$  alkyl or  $-OR^{10}$ . 20
  - The compound of claim 11, wherein at least one of  $R^4$ ,  $R^5$ 12. and  $R^6$  is H.
  - The compound of claim 12, wherein each of  $R^4$ ,  $R^5$  and  $R^6$ 25 13. are H.
    - The compound of claim 12, wherein one of  $R^4$ ,  $R^5$  and  $R^6$  is halogen.


- 15. The compound of claim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  and  $R^3$  are each H, and at least one of  $R^4$ ,  $R^5$  and  $R^6$  is H.
- 16. A compound of Formula (10) of, claim 1:

百0 切

<u>|</u>\_

**∐**5

20




or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is Me and  $R^6$  is H;
- a compound of Formula (10) wherein  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H; and
- a compound of Formula (10) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H.

-94-

25 17. A compound of Formula (20) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is Me and  $R^6$  is H;
- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;
- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
- a compound of Formula (20) wherein R<sup>4</sup> is F, R<sup>5</sup> is H and R<sup>6</sup> is F.
- 18. A compound of Formula (30) of claim 1:

- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is F;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is C1,  $R^5$  is H and  $R^6$  is H;
  - a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;
- 25 a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
  - a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;

D990E845 D7115

20

5

- a compound of Formula (30) wherein  $\mathbb{R}^3$  is H,  $\mathbb{R}^4$  is F,  $\mathbb{R}^5$  is H and  $\mathbb{R}^6$  is Cl;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and
  - a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is H.
- 19. A compound of Formula (40) of claim 1:

- or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:
  - a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
    - a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F and  $R^6$  is H;
- 25 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is F;
  - a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is H;

		/ 2
	a	compound of Formula (40) wherein R <sup>3</sup> is H, R <sup>4</sup> is H, R <sup>5</sup> is F
		and R <sup>b</sup> is H;
5	a	compound of Formula (40) wherein R <sup>3</sup> is H, R <sup>4</sup> is Cl, R <sup>5</sup> is
		H and R° is H;
	a	compound of Formula (40) wherein R <sup>3</sup> is H, R <sup>4</sup> is H, R <sup>5</sup> is
10		Cl and R° is H;
	a	compound of Formula (40) wherein $R^3$ is H, $R^4$ is H, $R^5$ is
.comb.		Cl and R <sup>6</sup> is F;
Q Q	a	compound of Formula (40) wherein R <sup>3</sup> is H, R <sup>4</sup> is H, R <sup>5</sup> is F
当5		and R <sup>6</sup> is Cl;
Ti Ci	a	compound of Formula (40) wherein R <sup>3</sup> is H, R <sup>4</sup> is F, R <sup>5</sup> is H
£ U		and R <sup>6</sup> is Cl;
	a	compound of Formula (40) wherein R is H, R is H, R is
		OMe and R <sup>6</sup> is H;
i D	a	compound of Formula (40) wherein R <sup>3</sup> is Me, R <sup>4</sup> is H, R <sup>5</sup> is
		H and R is H;
25	a	compound of Formula (40) wherein R <sup>3</sup> is Et, R <sup>4</sup> is H, R <sup>5</sup> is
,		H and R is H; and
	a	compound of Formula (40) wherein $R^3$ is $CH_2OH$ , $R^4$ is $H$ , $R^5$
30	•	is H and R is H.
	20.	A compound of Formula (50) of claim 1:

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (50) wherein R<sup>3</sup> is H, R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H.

21. A compound of Formula (6) of claim 1:

goreqs orthogo

20

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{1/3}$  is H;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;

	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is H, $R^5$ H, $R^6$ is H and $R^{13}$ is Et	is
5	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is H, $R^5$ F, $R^6$ is F and $R^{13}$ is H;	is
	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is H, $R^5$ F, $R^6$ is F and $R^{13}$ is Me;	is
10	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is F, $R^5$ H, $R^6$ is F and $R^{13}$ is H;	is
	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is F, $R^5$ H, $R^6$ is F and $R^{13}$ is Me;	is
	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is Cl, $R^5$ H, $R^6$ is H and $R^{13}$ is H;	is
<u>-</u> 20	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is Cl, $R^5$ H, $R^6$ is H and $R^{13}$ is Me;	is
	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is F, $R^5$ H, $R^6$ is H and $R^{13}$ is H;	is
25	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is H, $R^5$ F, $R^6$ is H and $R^{13}$ is H;	is
30	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is F, $R^5$ Cl, $R^6$ is H and $R^{13}$ is H;	is
	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is F, $R^5$ Cl, $R^6$ is H and $R^{13}$ is Me;	is
35	a compound of Formula (60) wherein $R^3$ is H, $R^4$ is Cl, $R^5$ F, $R^6$ is H and $R^{13}$ is H; and	is

- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is Me.
- 5 22. A compound of Formula (70) of claim 1:

- or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:
  - a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
  - a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me.
  - a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Et;
    - a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Bn;
- 25 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is H;
  - a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is Me;

20

PATENT

- 5 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:
  - a compound of Formula (80) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
  - a compound of Formula (80) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
  - a compound of Formula (80) Wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.
  - 24. A compound of Formula (90) of claim 1:

20

- a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.
- a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F; and
- a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H.
- 10
  25. A compound of Formula (100) of claim 1:

20

25

- a compound of Formula (100) wherein  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H.
- 26. A compound of Formula (110) of claim 1:

(110)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F;
  - a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
  - a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
  - a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
  - a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl; and
  - a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H.
  - 27. A compound of Formula (120) of claim 1:

R<sup>4</sup> R<sup>6</sup>

□5

OPOROPI DYLES

30

(120)

30

5


or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
  - a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F;
- 10 a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
  - a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
  - a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
  - a compound of Formula (220) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and
  - a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl.
  - 28. A compound of Formula (130) of claim 1:

(1)

- a compound of Formula (130) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H; and
- 5 a compound of Formula (130) wherein R<sup>4</sup> is H, R<sup>5</sup> is Bn and R<sup>6</sup> is H.
- 10 29. A compound of Formula (140)/of claim 1:

20



- or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:
  - a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
    - a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- 25 a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;
  - a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
  - a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;


- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H;
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.
  - 30. A compound of Formula (150) of claim 1:

25

- a compound of Formula (150) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- 20 a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
  - a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;
  - a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
  - a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and

- a compound of Formula (150) wherein  $\mathbb{R}^4$ is H,  $R^5$  is F and  $R^6$
- A compound of Formula (160) of claim 1: 31.

- or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:
  - a compound of Formula (160) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$ is H.
- A compound of Formula (170) of claim 1: 20 32.




T990ZZ45 OZIZOZ

25

30

5

- a compound of Formula (170) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
  - a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
- a compound of Formula (170) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F.
  - 33. A compound of Formula (180) of claim 1:



- or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:
  - a compound of Formula (180) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
  - a compound of Formula (180) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
  - a compound of Formula (180) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.
  - 34. A compound of Formula (190) of claim 1:

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (190) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H.

35. A compound of Formula (200) of claim 1:

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (200) wherein  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H; and

a compound of Formula (200) wherein  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me.

15

20

- 36. A compound of claim 1 selected from the group consisting
  of:

  (R)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,35 h]isoquinoline;
  - (S)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;
- (R) -7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2g]isoquinoline;
  - (S)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-g]isoquinoline;
  - (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
  - $(S)-4-(4-fluoro-phenyl)^{2}-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;$
  - (R) -4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h] isoquinoline;
  - (S)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;/
  - (R)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
  - (S)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (R) -4-(4-chloro-phenyl) -2-methyl-1,2,3,4-tetrahydro-35 furo[2,3-h]isoquinoline;
  - (S) -4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h] isoquinoline;
- 40 (R) -8-methyl-6-phenyl-2, 3, 6, 7, 8, 9-hexahydro-furo[3, 2-h] isoquinoline;
  - (S) -8-methyl 6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-h]isoquinoline;

글5

```
(R)-4-(4-fluoro-phenyl)-2-methyl/1,2,3,4-tetrahydro-
     furo[2,3-h]isoquinoline;
          (S)-4-(4-fluoro-phenyl)-2-methy1-1,2,3,4-tetrahydro-
  5
     furo [2,3-h] isoquinoline;
          (R)-4-(3,5-difluoro-pheny1)-2-methyl-1,2,3,4-tetrahydro-
     furo[2,3-h]isoquinoline;
 10
          (S)-4-(3,5-difluoro-pheny1)/2-methyl-1,2,3,4-tetrahydro-
     furo [2,3-h] isoquinoline;
          (R)-2-methyl-4-phenyl-2,3/4,7-tetrahydro-1H-pyrrolo[2,3-
     h]isoquinoline; and
(S)-2-methyl-4-phenyl-2;3,4,7-tetrahydro-1H-pyrrolo[2,3-
     h]isoquinoline.
          A compound of claim 1
                                  selected from the group consisting
     37.
     of:
          (+) -2-methyl-4-phenyl \frac{1}{4}, 2, 3, 4, 8, 9-hexahydro-furo [2, 3-
     h]isoquinoline;
          (-)-2-methyl-4-ph/en/yl/-1/2,3,4,8,9-hexahydro-furo[2,3-
40
     h]isoquinoline;
           (+)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-
 30
     g]isoquinoline;
          (-)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-
     g]isoquinoline;
 35
          (+)-4-(4-fluor \circ -phenyl)-2-methyl-1,2,3,4-tetrahydro-
     furo [2,3-h] isoquino/line;
          (-) -4 -(4 -fluo_{ro} -phenyl) -2 -methyl -1, 2, 3, 4 -tetrahydro
     furo[2,3-h]isoquinoline;
 40
          (+)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-
     furo[2,3-h]isoquinoline;
           (-) -4-(3,4 difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-
 45
     furo[2,3-h]isoquinoline;
```

- (+)-2-methyl-4-phenyl-1,2,3,4/tetrahydro-furo[2,3-h]isoquinoline;
- (-)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-5 h]isoquinoline;
  - (+)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (-) -4-(4-chloro-phenyl) -2'-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;

DOODSOFT DYLLD

- (+)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2h]isoquinoline;
- (-) -8-methyl-6-phenyl- $\frac{1}{2}$ , 3, 6, 7, 8, 9-hexahydro-furo[3, 2-h] isoquinoline;
- (+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (-)-4-(4-fluoro-phenyl) 2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (+)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (-) -4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h] isoquinoline;
- (+)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline; and
- (-)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-35 h]isoquinoline.
- 38. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically 40 effective amount of a compound of claim 1.
  - 39. A method of treating an animal afflicted with a neurological or psychological disorder selected from the group

deficit-hyperactivity disorder, consisting of attention fpost-traumatic disorder, depression, stress anxiety, supranuclear palsy, feeding disorders, obsessive compulsive analgesia/, /smøking cessation, panic 5 Parkinson's and phobia, said method comprising administering to the animal the pharmaceutical composition of claim 38.

40. The method of claim 39 for treating attention deficithyperactivity disorder.